We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

78 hedge funds and large institutions have $40.5M invested in Pyxis Oncology in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 36 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,800% more call options, than puts

Call options by funds: $290K | Put options by funds: $10K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

17% more capital invested

Capital invested by funds: $34.7M → $40.5M (+$5.8M)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

1% less funds holding

Funds holding: 79 → 78 (-1)

4.62% less ownership

Funds ownership: 48.5% → 43.88% (-4.6%)

69% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 36

Holders
78
Holders Change
-1
Holders Change %
-1.27%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
14
Increased
11
Reduced
36
Closed
14
Calls
$290K
Puts
$10K
Net Calls
+$280K
Net Calls Change
-$218K

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$695K
2
LCM
Laurion Capital Management
New York
+$303K
3
Renaissance Technologies
Renaissance Technologies
New York
+$242K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$217K
5
PAM
Panagora Asset Management
Massachusetts
+$105K

Top Sellers

1
Bank of America
Bank of America
North Carolina
-$861K
2
Jane Street
Jane Street
New York
-$726K
3
HP
HealthInvest Partners
Sweden
-$633K
4
Millennium Management
Millennium Management
New York
-$521K
5
ECM
ExodusPoint Capital Management
New York
-$365K
Name Holding Trade Value Shares
Change 		Change in
Stake
GSEP
76
Golden State Equity Partners
California
$14 +$15 +10 New
CIAM
77
Caitong International Asset Management
Hong Kong
$6 +$6 +4 New
SS
78
SBI Securities
Japan
$1 – – –
ECM
79
ExodusPoint Capital Management
New York
– -$365K -317,769 Closed
QC
80
Quadrature Capital
United Kingdom
– -$116K -100,536 Closed
OAC
81
OMERS Administration Corp
Ontario, Canada
– -$77K -67,000 Closed
VCIM
82
Velan Capital Investment Management
Georgia
– -$46K -40,000 Closed
HF
83
HRT Financial
New York
– -$45K -39,649 Closed
American Century Companies
84
American Century Companies
Missouri
– -$36.7K -31,936 Closed
LIP
85
Lighthouse Investment Partners
Florida
– -$33.2K -28,860 Closed
AF
86
Avanza Fonder
Sweden
– -$31.4K -27,345 Closed
EGM
87
Engineers Gate Manager
New York
– -$26.2K -22,816 Closed
Two Sigma Advisers
88
Two Sigma Advisers
New York
– -$26K -22,624 Closed
FRM
89
Fox Run Management
Connecticut
– -$26K -22,566 Closed
JFG
90
Jefferies Financial Group
New York
– -$18.4K -16,000 Closed
US Bancorp
91
US Bancorp
Minnesota
– -$108 -94 Closed
Northwestern Mutual Wealth Management
92
Northwestern Mutual Wealth Management
Wisconsin
– -$14 -12 Closed
1 2 3
4

PYXS Hedge Fund Activity: Q1 2026 in Review

78 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2026, worth a combined $40.5M — up 17% from $34.7M a quarter earlier.

Fund positioning in PYXS was balanced in Q1 2026: 14 funds opened new positions, 14 closed out, 11 added to existing stakes and 36 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $695K. The largest seller was Bank of America, cutting an estimated $861K.

  • 78 institutional investors held Pyxis Oncology (PYXS) as of Q1 2026, down from 79 in Q4 2025.
  • Funds reported $40.5M of Pyxis Oncology stock for Q1 2026, up 17% quarter-over-quarter.
  • 14 funds opened new Pyxis Oncology positions in Q1 2026 and 14 closed out, a net change of 0 holders.
  • The largest Pyxis Oncology buyer in Q1 2026 was Jacobs Levy Equity Management, an estimated $695K added.
  • The largest Pyxis Oncology seller in Q1 2026 was Bank of America, an estimated $861K sold.

Based on aggregated 13F filings for Q1 2026.